Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
COPENHAGEN, Denmark, Dec. 18, 2015 (GLOBE NEWSWIRE) -- Zealand today announces that the company's CEO Britt Meelby Jensen will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, 14 January 2016 at the Westin St. Francis Hotel in San Francisco, California. The presentation will take place at 10:30 am PT (7.30 pm CET).
The presentation will focus on the acceleration of Zealand's strategic direction towards value generation - from peptide to patient - and will outline the company's pipeline and news flow outlook for 2016.
An audio webcast of the presentation will be available on the Investor Relations section of the company's website at www.zealandpharma.com .
For further information, please contact:
Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications
Tel: +45 50 60 36 89, email: [email protected]
About Zealand Pharma
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia(r) by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus(r)) which is on track for regulatory submission in the US in Q4 2015 and in the European Union in Q1 2016.
The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics.
The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand's business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma
